After discontinuing the NVL-655 trial due to liver toxicity, ALK-positive patient and ALK Positive board member, Jeff Sturm, accessed the investigational drug zidesamtinib through a single-patient IND.

Read his experience here:
alkpositive.org/blog/patient...

#LearnAboutALKPositive

How much do you know about clinical trials? From placebos to safety to eligibility, there are a lot of myths out there.

Take our True or False Clinical Trials Quiz and see how you do! 🔬
alkpositive.org/blog/true-or...

#LearnAboutALKPositive #ALKPositive #ClinicalTrials #ALKResearch